Levobunolol - InSite Vision

Drug Profile

Levobunolol - InSite Vision

Alternative Names: BetaSite; Levobunolol

Latest Information Update: 22 Aug 2007

Price : $50

At a glance

  • Originator InSite Vision
  • Class Antiglaucomas; Antihypertensives; Propanolamines; Small molecules
  • Mechanism of Action Beta-adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Glaucoma

Most Recent Events

  • 08 Jan 2001 Profile reviewed but no significant changes made
  • 30 Dec 1997 Suspended-III for Glaucoma in USA (Ophthalmic)
  • 04 Sep 1996 Phase-III clinical trials for Glaucoma in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top